# Hypertensie bij kankeroverlevenden: VEGF-remmers, bloeddruklabiliteit en cardio-oncologie

*geplaatst 2026-11-17 · Hypertensie · Current hypertension reports · doi 10.1007/s11906-026-01394-3 · https://hartvaat.nl/2026/11/10/hypertensie-bij-kankeroverlevenden-vegf-remmers-bloeddruklabiliteit-en-cardio-on/*

Deze review beschrijft de hoge prevalentie en pathofysiologie van hypertensie bij kankeroverlevenden, met name in relatie tot VEGF-remmers, arteriële stijfheid en autonomicus dysfunction. Er wordt benadrukt dat orthostatische hypotensie en hypertensie vaak gelijktijdig voorkomen, wat het beheer bemoeilijkt. Voor de klinische praktijk betekent dit dat bloeddrukmanagement bij deze patiëntengroep vaak specialistische afstemming vereist, waarbij cardio-oncologische revalidatie en intensieve controle kunnen bijdragen aan het verminderen van cardiovasculaire morbiditeit.

## English: Hypertension and Blood Pressure Dysregulation in Cancer Survivors: Mechanisms, Management, and Future Directions.

This review examines the high prevalence and unique pathophysiology of hypertension in cancer survivors, highlighting the role of VEGF inhibitors, arterial stiffening, and autonomic dysfunction. A key finding is the frequent coexistence of orthostatic hypotension and hypertension, which complicates blood pressure management in this population. Clinically, this underscores the need for tailored antihypertensive strategies and cardio-oncology rehabilitation to mitigate cardiovascular morbidity, as current guidelines largely rely on general population targets.

## Abstract (original, from the publication)

PURPOSE OF REVIEW: This review examines the epidemiology, mechanisms, and management of hypertension in patients with cancer, emphasizing treatment-related hypertension, autonomic dysfunction, blood pressure lability, and evolving blood pressure targets in cardio-oncology. RECENT FINDINGS: Among cancer survivors both during and after their cancer treatment, hypertension is highly prevalent and is associated with increased cardiovascular morbidity and mortality. Vascular endothelial growth factor (VEGF) inhibitors are one of the most common causes of cancer treatment-induced hypertension, although other cancer treatments also contribute. Emerging evidence highlights the coexistence of orthostatic hypotension and hypertension, likely related to autonomic dysfunction, arterial stiffening, baroreflex impairment, and endothelial dysfunction related to cancer and its treatment. Medical management, intensive blood pressure control, and cardio-oncology rehabilitation may improve blood pressure control while mitigating adverse outcomes. Current hypertension management in cancer survivors largely follows general population guidelines despite the unique pathophysiology of cancer and its therapies. Future research should establish cancer-specific blood pressure targets, optimize antihypertensive strategies, and further investigate management of blood pressure lability, autonomic dysfunction, and cardio-oncology rehabilitation.

Auteurs: Lauren Daniel, W Gregory Hundley

---
Bron: Current hypertension reports, https://doi.org/10.1007/s11906-026-01394-3. Bijgewerkt 2026-11-11T02:12:03Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
